Notably, compared to non-glycosylated G-CSF, the glycosylated form showed improved stability in vitro, in vivo serum half-life and similar clinical outcomes in patients with neutropenia (Bönig et al., 2001; Tanaka et al., 1997; Watts et al., 1997). This evidence concerns the gene CSF3 and neutropenia.